Correction (Proceedings of the National Academy of Sciences of the United States of America (2014) DOI:10.1073/pnas.1416389112);HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 2, 2015, Pages E116-E175

  Kowalewski, Daniel J ^a   Schuster, Heiko ^a   Backert, Linus ^a   Berlin, Claudia ^a   Kahn, Stefan ^a   Kanz, Lothar ^a   Salih, Helmut R ^a,b   Rammensee, Hans Georg ^a,b   Stevanovic, Stefan ^a,b   Stickel, Juliane Sarah ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cancer immunotherapy; Chronic lymphocytic leukemia; HLA; Therapeutic vaccination; Tumor associated antigens

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; TUMOR ANTIGEN; CANCER VACCINE; HLA ANTIGEN; LIGAND; SUBUNIT VACCINE; T LYMPHOCYTE ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL; TARGET CELL; AGED; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CD4+ T LYMPHOCYTE; FEMALE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HLA ANTIGENS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIGANDS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; VACCINES, SUBUNIT;

EID: 84920998525     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1519135112     Document Type: Erratum

References (53)

1. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10(9):909-915.
2. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480-489.
3. Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P (2013) Database of T cell-defined human tumor antigens: The 2013 update. Cancer Immun 13:15.
4. Schwartzentruber DJ, et al. (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364(22):2119-2127.
5. Mittendorf EA, et al. (2012) Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 118(10):2594-2602.
6. Walter S, et al. (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18(8): 1254-1261.
7. Morgan RA, et al. (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36(2):133-151.
8. Ritgen M, et al. (2004) Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: Implications of minimal residual disease measurement with quantitative PCR. Blood 104(8):2600-2602.
9. Gribben JG, et al. (2005) Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106(13):4389-4396.
10. Russell NH, et al. (2005) Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 36(5):437-441.
11. Hallek M (2013) Signaling the end of chronic lymphocytic leukemia: New frontline treatment strategies. Blood 122(23):3723-3734.
12. Burkhardt UE, et al. (2013) Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest 123(9):3756-3765.
13. Giannopoulos K, et al. (2010) Peptide vaccination elicits leukemia-associated antigenspecific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia. Leukemia 24(4):798-805.
14. Giannopoulos K, Schmitt M (2006) Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 47(10):2028-2036.
15. Giannopoulos K, et al. (2006) Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol 29(1): 95-103.
16. Cobbold M, et al. (2013) MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med 5(203):ra125.
17. Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic significance. Oncogene 27(45):5869-5885.
18. Schipper RF, van Els CA, D'Amaro J, Oudshoorn M (1996) Minimal phenotype panels. A method for achieving maximum population coverage with a minimum of HLA antigens. Hum Immunol 51(2):95-98.
19. Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovic S (2002) Towards patient-specific tumor antigen selection for vaccination. Immunol Rev 188:164-176.
20. Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57.
21. Kanehisa M, Goto S (2000) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28(1):27-30.
22. Vargova K, et al. (2011) MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood 117(14):3816-3825.
23. Tran E, et al. (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344(6184):641-645.
24. Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer immunotherapy. Science 342(6165):1432-1433.
25. Wolchok JD, et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122-133.
26. Topalian SL, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-2454.
27. Hodi FS, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723.
28. Riley JL (2013) Combination checkpoint blockade-taking melanoma immunotherapy to the next level. N Engl J Med 369(2):187-189.
29. Perez SA, et al. (2010) A new era in anticancer peptide vaccines. Cancer 116(9): 2071-2080.
30. Cheever MA, et al. (2009) The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15(17):5323-5337.
31. van Rooij N, et al. (2013) Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31(32):e439-e442.
32. Robbins PF, et al. (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19(6):747-752.
33. van der Bruggen P, et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038):1643-1647.
34. Andersen RS, et al. (2012) Dissection of T-cell antigen specificity in human melanoma. Cancer Res 72(7):1642-1650.
35. Kvistborg P, et al. (2012) TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. OncoImmunology 1(4):409-418.
36. Berlin C, et al. (2014) Mapping the HLA ligandome landscape of acute myeloid leukemia: A targeted approach toward peptide-based immunotherapy. Leukemia, 10. 1038/leu. 2014. 233.
37. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393(6684): 480-483.
38. Janssen EM, et al. (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421(6925):852-856.
39. Mumberg D, et al. (1999) CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 96(15):8633-8638.
40. Greiner J, et al. (2012) Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood 120(6): 1282-1289.
41. Perez-Diez A, et al. (2007) CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109(12):5346-5354.
42. Sun JC, Williams MA, Bevan MJ (2004) CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 5(9): 927-933.
43. Tomita Y, et al. (2013) Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Clin Cancer Res 19(16):4508-4520.
44. Melief CJ (2013) "License to kill" reflects joint action of CD4 and CD8 T cells. Clin Cancer Res 19(16):4295-4296.
45. Vogelstein B, et al. (2013) Cancer genome landscapes. Science 339(6127):1546-1558.
46. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee HG (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351(6324):290-296.
47. Kowalewski DJ, Stevanovic S (2013) Biochemical large-scale identification of MHC class I ligands. Methods Mol Biol 960:145-157.
48. Käll L, Canterbury JD, Weston J, Noble WS, MacCoss MJ (2007) Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat Methods 4(11):923-925.
49. Sturm T, et al. (2013) Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons. Nat Commun 4:1616.
50. Widenmeyer M, et al. (2012) Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer 131(1):140-149.
51. Britten CM, et al. (2008) The CIMT-monitoring panel: A two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 57(3):289-302.
52. Neumann A, et al. (2013) Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer. Cancer Immunol Immunother 62(9):1485-1497.
53. Rudolf D, et al. (2008) Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother 57(2): 175-183.